Valuation dashboard for Oculis Holding AG (OCS) with P/E N/A, P/B 2.24, EV/EBITDA -6.79 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema.
Analysis Summary
Trailing-twelve-month margins: gross margin 35.2%, operating margin -358.7%, net margin -327.8%.
At the current price of $9.91, OCS has negative trailing earnings (P/E not meaningful) and an ROE of -42.92%. Market capitalisation stands at $567M.
Balance sheet quality for OCS: current ratio of 6.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.24 |
| EV / EBITDA | -6.79 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $1.83 |
| vs Current Price | -81.5% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| OCS | Oculis Holding AG | $567M | 2.24 | -42.9% | |
| KOD | Kodiak Sciences Inc. | $2.0B | 34.03 | -273.2% | |
| NRIX | Nurix Therapeutics, Inc. | $2.6B | 6.85 | -76.1% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
Price
| Price | $9.91 |
| Market Cap | $567M |
| Exchange | NASDAQ |
| Country | CH |
Profitability
| Return on Equity | -42.92% |
| Return on Invested Capital | -38.94% |
| Return on Assets | -31.82% |
| Gross Margin | 35.21% |
| Operating Margin | -35874.24% |
| Net Margin | -32780.20% |
Related companies: ANAB · BBOT · KOD · MNMD · NKTR · NRIX · PHAT
Explore sector: Healthcare · Biotechnology
More sections of OCS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks